Caribou Biosciences (CRBU) Citi's 2024 Global Healthcare Conference summary

Panel overview and strategic focus

• Leaders from three companies discussed advances in allogeneic cell therapies for autoimmune disorders, highlighting unique approaches and differentiation in the field.

• Emphasis on overcoming immune rejection, scalability, and off-the-shelf solutions to broaden patient access.

• Allogeneic CAR T and stem cell-derived therapies are being developed for both oncology and autoimmune indications, with a shift toward autoimmune focus in recent months.

• Off-the-shelf strategies are seen as critical for patient convenience and broader reach, especially in diseases like lupus.

• Panelists noted the importance of matching therapy modalities to disease heterogeneity and patient needs.

Company-specific innovations and clinical progress

• One company uses gene editing to knock out MHC class I/II and overexpress CD47, enabling scalable allogeneic cell production and immune evasion.

• Another focuses on off-the-shelf CAR T therapies, with CB-010 showing promise in oncology and now entering lupus trials; HLA matching improves outcomes.

• A third leverages induced pluripotent stem cells (iPSCs) for uniform, cost-effective NK and T cell production, with high product purity and scalability.

• Multiplexed engineering and unique edits, such as TRAC locus insertion and TCR knockout, enhance safety and efficacy in both oncology and autoimmune settings.

• Clinical data show effective B cell depletion, immune reset, and promising safety profiles in early autoimmune trials.

Pipeline updates and upcoming milestones

• Key upcoming data include results from gene-modified islet transplants for type 1 diabetes and allogeneic CAR T programs targeting B cell-mediated autoimmune diseases.

• CB-010 pivotal trial in oncology is planned, with additional cohorts in lupus and relapsed/refractory settings; HLA matching strategy is being validated.

• Multiple myeloma and AML programs are advancing, with unique targets and immune cloaking strategies under evaluation.

• FT819 and FT825 are highlighted as lead assets in autoimmune and solid tumor indications, with new data expected soon.

• Companies are optimistic about near-term data readouts and the potential for curative therapies in autoimmune diseases.